<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="39015">Apolipoprotein</z:chebi> E (APOE) genotype was determined in a population of patients with <z:hpo ids='HP_0000726'>dementia</z:hpo>, including 735 patients with <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD), 75 with <z:e sem="disease" ids="C0751072" disease_type="Mental or Behavioral Dysfunction" abbrv="FTLD">Frontotemporal Lobar Degeneration</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FTLD</z:e>), 97 with Vascular <z:hpo ids='HP_0000726'>Dementia</z:hpo> (VaD) and 40 with Lewy Body <z:hpo ids='HP_0000726'>Dementia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBD</z:e>), as well as in 506 age- and gender-matched controls (CON) </plain></SENT>
<SENT sid="1" pm="."><plain>APOE ε2 allele frequency was lower in patients with AD (2.8%) than in CON (6.4%, P≤0.001, OR: 0.41) </plain></SENT>
<SENT sid="2" pm="."><plain>Similar results were obtained comparing AD with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FTLD</z:e> (6.7%, P≤0.01, OR: 0.37), at difference from VaD (5.6%, P&gt;0.05) or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBD</z:e> (5.0%, P&gt;0.05) </plain></SENT>
<SENT sid="3" pm="."><plain>The frequency of the APOE ε4 allele was increased in patients with AD (25.1%) as compared with CON (8.2%, P≤0.001, OR: 4.24), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FTLD</z:e> (11.3%, P≤0.001, OR: 2.67), VaD (11.8%, P≤0.001, OR: 3.02), or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBD</z:e> (13.8%, P=0.048, OR: 2.07) </plain></SENT>
<SENT sid="4" pm="."><plain>The frequency of the ε4/ε4 genotype was increased in AD patients compared with controls (6.3 versus 0.8%, P≤0.001, OR: 8.38) </plain></SENT>
<SENT sid="5" pm="."><plain>The presence of the ε2 allele is a protective factor for AD, whereas the ε4 allele acts as a risk factor for the disease </plain></SENT>
<SENT sid="6" pm="."><plain>Both alleles do not influence the susceptibility to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FTLD</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBD</z:e> and VaD </plain></SENT>
</text></document>